Oryzon Genomics Expands Patent Coverage for Vafidemstat Therapy
Oryzon Genomics, S.A., a leading European biopharmaceutical company in the field of epigenetics and headquartered in Barcelona, Spain, is making significant strides in its patented research. The European Patent Office has recently issued a favorable decision regarding the patent application for vafidemstat, which is an innovative treatment method aimed at Attention Deficit Hyperactivity Disorder (ADHD).
This European patent is titled "Methods of treating Attention Deficit Hyperactivity Disorder using KDM1A inhibitors such as the compound vafidemstat." The confirmation that this application has met the rigorous standards set by the Patent Office is a major milestone for Oryzon, marking the patent's potential validity until at least 2040, with prospects for extension. The company is also pleased to report that a similar patent has been granted in Japan, paving the way for further international protection.
Significance of Oryzon's Patent Portfolio
Neus Virgili, Chief IP Officer at Oryzon, expressed the company's excitement about these newly granted patents. He stated, "These new patent allowances in Europe and Japan complement the ample portfolio we’ve already secured for vafidemstat, further strengthening our global IP position and supporting the compound’s commercial potential across multiple CNS indications and our competitive position." This statement highlights Oryzon's strategic vision for leveraging its intellectual property to enhance its market stance in the biopharmaceutical industry.
Oryzon has established a comprehensive patent portfolio for vafidemstat that encompasses multiple indications in the central nervous system (CNS). This portfolio includes two additional patent families that focus on the treatment of aggression and social withdrawal, as well as borderline personality disorder.
Patents for Additional Indications
For aggression and social withdrawal, Oryzon has secured patents in various regions, including Europe, Australia, and Russia, effective until at least 2038. This provides Oryzon with a strong foundation to protect its innovations during a crucial period of clinical development.
The second patent family addresses treatments for borderline personality disorder, with allowances secured in numerous territories such as Japan and South Africa. This not only demonstrates Oryzon's capability to innovate but also enhances the therapeutic options available for patients suffering from severe mental health conditions.
Oryzon's Commitment to CNS Disorders
Oryzon Genomics was founded in 2000 and has since grown to become a leader in the epigenetics field, particularly with its focus on personalized medicine in CNS disorders and oncology. The company's pioneering efforts in developing LSD1 inhibitors, such as vafidemstat, are at the forefront of clinical research.
Vafidemstat, scientifically known as ORY-2001, acts as an oral LSD1 inhibitor optimized for CNS applications, targeting a range of cognitive impairments and neuroinflammation. Its multi-faceted approach has shown promising results in preclinical models, including the restoration of cognitive functions and reduction in aggressive behavior among symptomatic mice models.
Clinical Development and Future Prospects
The clinical progress made with vafidemstat is notable. Several trials are underway, including the REIMAGINE studies that focus on aggressiveness in psychiatric patients and individuals diagnosed with Alzheimer’s disease. The results have been overwhelmingly positive, bolstering Oryzon's knowledge and application of vafidemstat as a leading treatment option.
The company is not only exploring vafidemstat in prevalent CNS disorders but also extending its research to evaluate the drug's efficacy in genetic disorders and other neurodevelopmental conditions, positioning itself as a pioneer in this vital area of healthcare.
Contacting Oryzon Genomics
Oryzon remains committed to transparency and open communication with stakeholders and the public. Interested parties may contact the company directly for inquiries or further information regarding their innovative projects and clinical studies.
Frequently Asked Questions
What is the significance of Oryzon's new patents?
The patents enhance Oryzon's intellectual property protection for vafidemstat, securing their innovations in Europe and Japan and supporting the commercialization of treatments for CNS disorders.
How does vafidemstat work?
Vafidemstat is an LSD1 inhibitor that targets CNS disorders, aiming to improve cognitive functions and mitigate neuroinflammation associated with various psychiatric conditions.
What types of disorders is Oryzon targeting with vafidemstat?
Oryzon is primarily targeting disorders such as ADHD, borderline personality disorder, and Alzheimer's disease, among others related to mental health and neurodevelopment.
How long will the patents for vafidemstat last?
The patents are expected to remain in force until at least 2040, providing Oryzon with the potential for extended protection through additional patent term extensions.
Where can I find more information about Oryzon Genomics?
More information is available on the company’s official website, where updates on clinical trials and patent developments can be accessed.
